While UroGen Pharma Ltd has overperformed by 4.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, URGN fell by -23.54%, with highs and lows ranging from $20.70 to $9.03, whereas the simple moving average fell by -19.62% in the last 200 days.
On February 19, 2025, Ladenburg Thalmann started tracking UroGen Pharma Ltd (NASDAQ: URGN) recommending Buy. A report published by Guggenheim on August 22, 2024, Initiated its previous ‘Buy’ rating for URGN. Jefferies also Downgraded URGN shares as ‘Hold’, setting a target price of $10 on the company’s shares in a report dated February 08, 2023. Berenberg Initiated an Buy rating on April 27, 2022, and assigned a price target of $20. H.C. Wainwright resumed its ‘Buy’ rating for URGN, as published in its report on April 16, 2020. H.C. Wainwright’s report from April 13, 2020 suggests a price prediction of $53 for URGN shares, giving the stock a ‘Buy’ rating. National Securities also rated the stock as ‘Neutral’.
Analysis of UroGen Pharma Ltd (URGN)
Further, the quarter-over-quarter increase in sales is 4.40%, showing a positive trend in the upcoming months.
UroGen Pharma Ltd’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. Taking into account the quick ratio of the company, currently set at 5.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and URGN is registering an average volume of 390.69K. On a monthly basis, the volatility of the stock is set at 6.43%, whereas on a weekly basis, it is put at 9.38%, with a loss of -9.82% over the past seven days. Furthermore, long-term investors anticipate a median target price of $34.86, showing growth from the present price of $10.10, which can serve as yet another indication of whether URGN is worth investing in or should be passed over.
How Do You Analyze UroGen Pharma Ltd Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.09%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.29% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
URGN shares are owned by institutional investors to the tune of 80.29% at present.
